Gilead Sciences, Inc. (GILD) said that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis, is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration on December 10, 2009.
In September 2009, the product was granted conditional marketing approval in Canada and Europe under the trade name Cayston. Applications for marketing approval of Cayston are also pending in Australia, Switzerland and Turkey, the company noted.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.